OXytocin For Opioid Respiratory Depression (OXFORD)
A Prospective, Single-center, Randomized, Double-blinded Study to Evaluate the Therapeutic Efficacy of Intranasal Oxytocin in Decreasing the Severity of Sleep Disordered Breathing, Pain Perception, Opioid Dose and Drug Liking in Patients on Chronic Opioid Therapy for Chronic Pain
Opioid medications are a significant component of the management of chronic pain. Chronic use of opioids disrupts sleep architecture and cause respiratory depression, which is particularly prevalent during sleep. Chronic opioids induce sleep disordered breathing (SDB) including sleep hypoventilation, central sleep apnea and obstructive sleep apnea (OSA). It was previously shown that oxytocin can treat SDB. There is emerging evidence that oxytocin can treat substance use disorder and has analgesic properties. Oxytocin efficacy of prevention of respiratory depression after acute opioid use will be examined as well as oxytocin efficacy in chronic opioid use.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Intranasal oxytocin to prevent opioid-induced respiratory depression, reduce pain and the opioid dose in patients on chronic opioids (OXytocin For Opioid Respiratory Depression). OXFORD will test in a double blinded, placebo-controlled phase 2 clinical trial, the therapeutic efficacy of OXYTOCIN in decreasing A) the severity of sleep disordered breathing (SDB); B) pain perception, C) the opioid dose and D) drug liking in patients on chronic opioid therapy for chronic pain. Opioid medications are a significant component of the management of chronic pain. Chronic use of opioids disrupts sleep architecture and cause respiratory depression, which is particularly prevalent during sleep. Chronic opioids induce SDB including sleep hypoventilation, central sleep apnea and OSA. It was previously shown that OXYTOCIN can treat Sleep Disordered Breathing (SDB). There is emerging evidence that OXYTOCIN can treat substance use disorder and has analgesic properties. OXFORD will examine OXYTOCIN efficacy for prevention of respiratory depression after acute opioid use.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Eduard R Research Manager
- Telefonnummer: 2022038960
- E-mail: eshaykhinurov@mfa.gwu.edu
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- ≥ 18 years of age
- Treated for chronic pain with ≥ 30 milligram morphine equivalent (MME)
- Able and willing to provide informed consent
- Women of childbearing potential will be required to use a highly effective form of contraception in order to be included in the study
Exclusion Criteria:
- OSA patients on CPAP therapy
- Baseline home sleep testing with > than 10 minutes with a baseline oxygen saturation <=85%
- Unstable cardiovascular disease (decompensated CHF, myocardial infarction or revascularization procedures, and unstable arrhythmias)
- Uncontrolled hypertension (BP > 190/110)
- Chronic Obstructive Pulmonary Disease or another intrinsic lung disease
- Chronic sinusitis requiring surgical treatment (except septal deviation)
- Chronic muscle weakness
- Chronic daytime hypoxemia (PaO2 < 70) or hypercapnia (PaCO2 ≥ 45 mmHg)
- Chronic supplemental oxygen use
- Renal failure on dialysis
- Diabetes mellitus requiring insulin
- Diabetic neuropathy
- Previous surgery for OSA (laser-assisted uvulopalatoplasty, LAUP or uvulopalatopharyngoplasty)
- Hypoglossal nerve stimulator
- Allergy to oxytocin
- Pregnancy
- Premenopausal women, who are not on birth control
- Any change in non-opioid medications and non-pharmacological interventions during the OXYTOCIN trial
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Intranasal Oxytocin
Intranasal oxytocin |
Intranasal oxytocin dose of 40 international units |
|
Placebo komparator: Intranasal Placebo
Intranasal placebo |
This is a placebo comparator intranasal spray |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Hypopnea on home sleep testing
Tidsramme: Beginning of study (Day 1, baseline) and the night before day 28 visit
|
Number of hypopnea events on home sleep testing |
Beginning of study (Day 1, baseline) and the night before day 28 visit
|
|
Oxytocin Level
Tidsramme: During day 28 visit
|
Urinary level of oxytocin |
During day 28 visit
|
|
Respiratory Rate
Tidsramme: Baseline (Day 1) and second sleep apnea testing (the night before day 28 visit)
|
Duration of significant increases in respiratory rate |
Baseline (Day 1) and second sleep apnea testing (the night before day 28 visit)
|
|
Short form McGill Questionnaire
Tidsramme: Day 1 and Day 30 of study
|
0-45, higher is more pain |
Day 1 and Day 30 of study
|
|
Visual Analogue Pain Scale
Tidsramme: Day 1 and Day 30 of study
|
0-10, higher is more pain |
Day 1 and Day 30 of study
|
|
Drug liking and high questionnaire
Tidsramme: Day 1 and Day 30 of study
|
0-16, higher is more drug effect from pain medications |
Day 1 and Day 30 of study
|
|
Short form brief pain inventory
Tidsramme: Day 1 and Day 30 of study
|
0-120, higher is more pain |
Day 1 and Day 30 of study
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- OXFORD-GWU-2
- UG3DA062506-02 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .